352Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations. (28th August 2018) - Hopkins, P N; Krempf, M; Bruckert, E; Luc, G; Donahue, S; Yang, F; Zhang, Y; Dicioccio, A T